Clinical trialNCT04513717Active, not recruitingPhase 3Interventional

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

SponsorNRG OncologyEnrollment2,753Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Paul L Nguyen
NRG Oncology
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

602 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario, Canada
University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
the Research Institute of the Mcgill University Health Centre (muhc)
Montreal, Quebec, Canada
Chu de Quebec-L'Hotel-Dieu de Quebec (hdq)
Québec, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Sherbrooke, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada

United States

Fairbanks Memorial Hospital
Fairbanks, Alaska, United States
Arizona Center for Cancer Care - Gilbert
Gilbert, Arizona, United States
Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
Arizona Center for Cancer Care-Peoria
Peoria, Arizona, United States
Arizona Center for Cancer Care - Phoenix
Phoenix, Arizona, United States
Arizona Center for Cancer Care - Scottsdale
Scottsdale, Arizona, United States
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States
Ais Cancer Center at San Joaquin Community Hospital
Bakersfield, California, United States
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California, United States
Enloe Medical Center
Chico, California, United States
City of Hope Corona
Corona, California, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Kaiser Permanente Dublin
Dublin, California, United States
Uc San Diego Health System - Encinitas
Encinitas, California, United States
Kaiser Permanente-Fremont
Fremont, California, United States
Palo Alto Medical Foundation-Fremont
Fremont, California, United States
Washington Hospital
Fremont, California, United States
Kaiser Permanente-Fresno
Fresno, California, United States
Marin General Hospital
Greenbrae, California, United States
City of Hope at Irvine Lennar
Irvine, California, United States
Uci Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
Uc San Diego Moores Cancer Center
La Jolla, California, United States
City of Hope Antelope Valley
Lancaster, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Los Angeles General Medical Center
Los Angeles, California, United States
Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Fremont - Rideout Cancer Center
Marysville, California, United States
Kaiser Permanente-Modesto
Modesto, California, United States
Memorial Medical Center
Modesto, California, United States

562 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Apalutamide →Bicalutamide →BuserelinDegarelix →Flutamide →Goserelin →HistrelinLeuprolide →Relugolix →Triptorelin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Jan 2021
Primary completion: 31 Dec 2033
Completion: 31 Dec 2038
Last update posted: 17 Aug 2026
Registered enrollment: 2,753
Registry id: NCT04513717

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.